Debu Tripathy, editor-in-chief of CURE magazine, discusses updates from the Miami Breast Cancer Conference, including the changing landscape of HER2-positive breast cancer.
Debu Tripathy, editor-in-chief of CURE magazine, discusses updates from the Miami Breast Cancer Conference, including the changing landscape of HER2-positive breast cancer.
HER2-targeted therapies have evolved rapidly since the arrival of Herceptin (trastuzumab) more than 15 years ago. New therapies, such as Perjeta and Kadcyla, have further improved outcomes, but now we are looking at the best way to use all these treatments and in what sequence.
"It's important for patients to be aware of what the landscape is," he says, so they can have informed discussions with their oncologists on what is the best course of treatment for them.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Listen
Rethinking Physical and Mental Health Throughout the Breast Cancer Journey
March 17th 2024A patient advocate and oncology nurse discuss the importance of physical and mental health during the breast cancer journey during a panel session at the CURE® Educated Patient® Breast Cancer Summit.
Read More
Olivia Munn Discusses Breast Cancer, Christine Brinkley Diagnosed With Basal Cell Carcinoma and More
March 15th 2024From Oliva Munn and Christine Brinkley discussing their cancer to Donnie Iris returning to the stage after his experience with the disease, here is what’s happening in the oncology space this week.
Read More